SciMed Biotech Podcast with Joanna Brewer of Adaptimmune

The future of cancer immunotherapy with Joanna Brewer of Adaptimmune

Brace yourself for a journey into the world of cutting-edge cancer immunotherapy! In this episode of the SciMed Biotech podcast, we sit down with Dr. Joanna Brewer, the Chief Scientific Officer of Adaptimmune, a pioneering force in T-cell therapy. Get ready to uncover the incredible story of how science is transforming the lives of cancer patients. 

Dr. Brewer, with over two decades of experience in immunotherapy and cell therapy, shares her remarkable journey from founding scientist to leading one of the most innovative companies in the field. She's been instrumental in developing groundbreaking TCR T-cell therapies, and her expertise has paved the way for treatments like afami-cel, offering hope to those battling synovial sarcoma. 

Join us as we dive deep into the world of SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell therapies, designed to harness the body's own T-cells to target and destroy cancer cells. Discover how Adaptimmune's proprietary TCR platform is revolutionizing cancer treatment, and hear about their exciting next-generation approaches, including ADP-A2M4CD8 and HiT therapies. 

In this episode, Dr. Brewer takes us behind the scenes of the battle against cancer, sharing insights from translational research, patient outcomes, and the future of cell therapy. If you're passionate about the potential of science to save lives and eager to learn about the groundbreaking work happening at Adaptimmune, this episode is a must-listen! 

Join us on this journey to uncover the life-changing impact of T-cell therapy with Dr. Joanna Brewer, and discover why Adaptimmune is at the forefront of cancer immunotherapy.